<DOC>
	<DOCNO>NCT00952939</DOCNO>
	<brief_summary>RATIONALE : Studying sample tumor tissue patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . PURPOSE : This clinical trial study tumor sample patient undergo surgery radiation therapy primary melanoma eye .</brief_summary>
	<brief_title>Study Tumor Samples Patients Undergoing Radiation Therapy Surgery For Primary Melanoma Eye</brief_title>
	<detailed_description>OBJECTIVES : Primary - To establish feasibility use fine needle aspiration ( FNA ) FISH determine tumor genotype patient primary uveal melanoma . Secondary - To characterize ophthalmic complication rate FNA FISH analysis patient undergo plaque radiotherapy . - To estimate disease-free survival patient without tumor monosomy 3 and/or 8q amplification . - To explore relationship tumor monosomy 3 8q amplification plasma level tumor immune escape invasion biomarkers ( e.g. , circulate granulysin , beta2-microglobulin , autotoxin , lysophosphatidic acid , matrix metalloproteinase-7 , tissue inhibitor matrix metalloproteinase , soluble E- cadherin ) . - To explore psychological impact prognostication uveal melanoma . OUTLINE : Patients undergo plaque radiotherapy , enucleation , tumor resection base upon standard care guideline . Trans-scleral fine needle aspiration ( FNA ) perform time plaque radiotherapy ex vivo FNA perform enucleation tumor resection specimen . Tissue sample analyze fluorescence situ hybridization ( FISH ) . Blood sample also collect analysis . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Patients must clinical diagnosis melanoma iris , ciliary body and/or choroids Patients must hepatic ultrasound and/or suitable image study eliminate metastatic disease Patients must receive local systemic therapy uveal melanoma All patient must inform investigational nature study must provide write informed consent accordance institutional federal guideline . A copy inform consent document sign patient must give patient Patients must follow pretreatment laboratory finding : Bilirubin ( total ) &lt; /= 1.5 ml/dl AST &lt; /= 2 x normal ALT &lt; /= 2 x normal Alkaline phosphatase &lt; /= 2 x normal Exclusion Criteria Patients metastasis Patients age 18</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>ciliary body choroid melanoma , small size</keyword>
	<keyword>iris melanoma</keyword>
	<keyword>intraocular melanoma</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
</DOC>